Synaffix BV news
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces the Company has been awarded ‘Biotech Company of the Year 2022’ at the annual LSX, European Lifestars Awards Ceremony, held on the 14th o
- Synaffix obtains exclusive rights to the CliCr® technology, to combine with its proprietary ADC platform technology
- CliCr® further expands the repertoire of payloads suitable for conjugation by enhancing reactivity, stability and hydrophilicity
Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-i
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company was awarded ‘Best ADC Platform Technology’ at the World ADC Conference 2022.
This marks the second time that Synaffix’ groundbreaking ADC platform technology has been acknowledged as industry-leading by winning 1st
- Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker-payload)
- Emergence Therapeutics secures rights to develop multiple ADCs against undisclosed targets to strengthen its ADC pipeline
- Emergence Therapeutics becomes the tenth company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 million, plus royalties
- Kyowa Kirin expands the license agreement with one new ADC to a total of three ADC programs
- Kyowa Kirin also exercises exclusive target option for development and commercialization against an undisclosed ADC target
- Decisions driven by highly competitive preclinical therapeutic index demonstrated by Kyowa Kirin’s lead program that was built by using Synaffix ADC technology
- Triggers $5 million immediate payment to Synaffi
- Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
- MacroGenics to combine proprietary antibody and bispecific DART® technology with Synaffix’s linker-payload technologies to develop up to three next generation conjugates
- Total potential deal value of up to $586 million, plus royalties on commercial sales
Synaffix B.V., a biotechnology company focused on commercializing its clinica
- Synaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
- Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
- Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales of successfully commercialized t
- Expanded deal focuses on Synaffix’s GlycoConnect™ site-specific ADC bioconjugation technology and adds license options for six new programs to existing deal
- Mersana currently developing two programs based on GlycoConnect™ site-specific ADC bioconjugation technology (XMT-1592 and XMT-1660)
Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-d
- Winning scientific poster shows complete tumor regression and high tolerability of SYNtecan E™ based ADCs
- SYNtecan E™ linker-payload is developed by Synaffix based on the potent DNA topoisomerase 1 inhibiting exatecan
- Additionally, Synaffix was awarded ‘Runner-Up’ for the 2021 Best ADC Platform Technology (Winner in 2020)
Synaffix B.V., a biotechnology company focused on commercializing its clinical-